Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Prices IPO at $10 per Share

NEW YORK (GenomeWeb News) – NanoString Technologies late on Tuesday priced its planned initial public offering at $10 per share.

The company expects to offer 5.4 million shares of its common stock in the offering. In a prospectus filed today, NanoString said that it anticipates net proceeds from the offering of about $50.2 million.

Additionally, it has granted the underwriters a 30-day option to purchase up to 810,000 shares to cover any over-allotments.

JP Morgan and Morgan Stanley are the book-running managers, while Leerink Swann and RW Baird are co-managers. NanoString plans to trade on the Nasdaq Global Market under ticker symbol "NSTG".

Seattle-based NanoString announced its plans to go public a month ago with a proposed maximum aggregate offering price of about $86.3 million. Two weeks ago, it said that the share price on the offering was expected to be between $13 and $15, which would have brought in as much as $77.6 million.

The firm said that it would use proceeds from the offering to commercialize its Prosigna Breast Cancer Assay after receiving US regulatory authorization, including the creation of a dedicated oncology sales force; support and grow the installed base of its nCounter molecular analysis systems among life science research customers; and develop new life sciences applications, chemistry, and instrumentation for the nCounter platform.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.